BACKGROUND: Prostate cancer is considered a major health problem in western countries. Promising results from observational studies on cancer at other sites fuelled the publication of several studies assessing the association between nonsteroidal anti-inflammatory drug (NSAID) use and prostate cancer. However, these studies show conflicting results. METHODS: We conducted a cohort study with a nested case-control analysis to further study the association between NSAIDs and prostate cancer. We used data from the General Practice Research Database in United Kingdom. RESULTS: Aspirin use was associated with a reduced risk of prostate cancer [odds ratio (OR) = 0.70, 95% confidence interval (95% CI) = 0.61-0.79]. We also found that paracetamol use with a treatment duration longer than 1 year was associated with a decreased risk (OR = 0.65, 95% CI = 0.54-0.78). Non-aspirin-NSAID (NA-NSAID) and paracetamol short-term use was associated with a small increased risk whereas long-term users of NA-NSAIDs presented an OR of 0.89 (95% CI = 0.73-1.08). DISCUSSION: Our findings support a protective effect of aspirin and paracetamol against prostate cancer. The transient elevated risk observed among newly started users of NA-NSAIDs and paracetamol is most likely explained by prothopathic bias. We found some suggestion of a reduced risk with long-term use of NA-NSAID.
BACKGROUND:Prostate cancer is considered a major health problem in western countries. Promising results from observational studies on cancer at other sites fuelled the publication of several studies assessing the association between nonsteroidal anti-inflammatory drug (NSAID) use and prostate cancer. However, these studies show conflicting results. METHODS: We conducted a cohort study with a nested case-control analysis to further study the association between NSAIDs and prostate cancer. We used data from the General Practice Research Database in United Kingdom. RESULTS:Aspirin use was associated with a reduced risk of prostate cancer [odds ratio (OR) = 0.70, 95% confidence interval (95% CI) = 0.61-0.79]. We also found that paracetamol use with a treatment duration longer than 1 year was associated with a decreased risk (OR = 0.65, 95% CI = 0.54-0.78). Non-aspirin-NSAID (NA-NSAID) and paracetamol short-term use was associated with a small increased risk whereas long-term users of NA-NSAIDs presented an OR of 0.89 (95% CI = 0.73-1.08). DISCUSSION: Our findings support a protective effect of aspirin and paracetamol against prostate cancer. The transient elevated risk observed among newly started users of NA-NSAIDs and paracetamol is most likely explained by prothopathic bias. We found some suggestion of a reduced risk with long-term use of NA-NSAID.
Authors: Claudia A Salinas; Erika M Kwon; Liesel M FitzGerald; Ziding Feng; Peter S Nelson; Elaine A Ostrander; Ulrike Peters; Janet L Stanford Journal: Am J Epidemiol Date: 2010-08-05 Impact factor: 4.897
Authors: Nancy A Shadick; Elizabeth W Karlson; Nancy R Cook; Nancy E Maher; Julie E Buring; I-Min Lee Journal: Arthritis Care Res (Hoboken) Date: 2010-04 Impact factor: 4.794
Authors: Adriana C Vidal; Lauren E Howard; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland Journal: Clin Cancer Res Date: 2014-12-17 Impact factor: 12.531
Authors: Jay H Fowke; Saundra S Motley; Joseph A Smith; Michael S Cookson; Raoul Concepcion; Sam S Chang; Susan Byerly Journal: J Urol Date: 2009-03-14 Impact factor: 7.450
Authors: Aditya Bardia; Elizabeth A Platz; Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson Journal: Curr Opin Pharmacol Date: 2009-07-01 Impact factor: 5.547